Greetings,
I am Adrian H. Kim, CEO of DREAMPAC Corp.

DREAMPAC was founded to bring new hope to patients with peritoneal metastasis through the development of advanced biomedical devices and innovative treatment approaches. We are leading progress in the field of intraperitoneal chemotherapy, a globally recognized area of cancer treatment, including pressurized intraperitoneal aerosol chemotherapy (PIPAC) and hyperthermic intraperitoneal chemotherapy (HIPEC). Through continuous research and innovation, we strive to improve patients’ quality of life and help advance the paradigm of cancer treatment.

Intraperitoneal chemotherapy represents an important turning point in the treatment of peritoneal metastasis. It offers new therapeutic opportunities to patients immediately after surgery or to those with recurrent disease due to multi-drug resistance—supporting improved survival outcomes, prognosis, and quality of life. Through the development of medical devices and clinical solutions, DREAMPAC is working to establish new standards of care and expand practical adoption in clinical settings, opening new horizons in treatment.

Going forward, DREAMPAC will continue to focus on research and development so that more patients can receive safe and effective treatment, built on the trust of both patients and medical professionals. We are committed to medical innovation and social responsibility, and we will continue to move forward to help deliver better health and hope to all patients suffering from peritoneal metastasis.

Thank you.